达格列净在苏丹心力衰竭患者中的实际应用、安全性和临床结果:一项多中心回顾性队列研究
Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study
一项多中心回顾性队列研究显示,达格列净在苏丹心力衰竭患者中的使用具有良好的依从性,治疗后左心室射血分数有所改善,且安全性可接受。研究纳入238名患者,结果显示治疗后患者的心功能和血糖控制均有改善,但仍有心血管死亡和心力衰竭再住院的风险。
- Article
- Open access
- Published: 04 October 2026
- Manasik Nasreldeen1,
- Toga K. Mohamed2,
- Anas Babiker3,
- Bashir A. Yousef4,5,
- Emmanuel Edwar Siddig6,7 &
- …
- Kannan O. Ahmed ORCID: orcid.org/0000-0002-1829-56158,9
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, provides glycemic control and has proven cardiovascular and renal benefits in large trials, but its real-world use in Sudan has not been described. This study aimed to describe clinical characteristics, safety, adherence, and outcomes among Sudanese patients prescribed dapagliflozin in routine care. A multicenter retrospective cohort study (April–July 2022) was conducted at three cardiac hospitals in Khartoum, Sudan. Adults (n = 238) prescribed dapagliflozin for heart failure (HF) were enrolled. Data were obtained from medical records and structured patient interviews, capturing sociodemographic data, adverse events, adherence, hospitalizations, and deaths. Mean age was 60.7 ± 12 years; 55% were male. 96.3% of patients received dapagliflozin at a starting dose of 10 mg once daily. High adherence was reported in 86.1%. Common adverse events were polyuria (65.1%) and urinary tract infection (32.8%). Following dapagliflozin therapy, mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001), whereas HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001). Cardiovascular death was observed in 4.6% of patients, and HF hospitalization occurred in 7.6%. In this first Sudanese real-world cohort, dapagliflozin was associated with good adherence, observed improvement in LVEF, and an acceptable safety profile, supporting its role in cardiac care in low-resource settings.
Acknowledgements
The authors are thankful to all the participants who contributed to and helped facilitate the conduct of this study.
Author information
Authors and Affiliations
Department of Clinical Pharmacy, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan
Manasik Nasreldeen
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum, Sudan
Toga K. Mohamed
Department of Cardiology, Royal Care International Hospital, Khartoum, Sudan
Anas Babiker
Department of Clinical Pharmacy and Pharmacology, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia
Bashir A. Yousef
Department of Pharmacology, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
Bashir A. Yousef
Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan
Emmanuel Edwar Siddig
Pan Africa Biomedical Institute, Kigali, Rwanda
Emmanuel Edwar Siddig
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, University of Gezira, Wad Medani, Sudan
Kannan O. Ahmed
Department of Pharmacy Practice, College of Pharmacy, National University of Science and Technology, Muscat, Oman
Kannan O. Ahmed
Authors
- Manasik Nasreldeen
- Toga K. Mohamed
- Anas Babiker
- Bashir A. Yousef
- Emmanuel Edwar Siddig
- Kannan O. Ahmed
Corresponding author
Correspondence to Kannan O. Ahmed.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The study adhered to the Declaration of Helsinki guidelines. The study received ethical approval (Ref No: KMOH-REC-024.2-2022) from the Sudanese Ministry of Health’s Review and Research Ethics Board, additional approvals were obtained from each hospital from which patients were recruited and data were gathered. A written informed consent was obtained from all the study participants prior to the data collection process. Additionally, permission to use the Morisky Medication Adherence Scale (MMAS) was obtained from the copyright holder, MMAS Research LLC.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Nasreldeen, M., Mohamed, T.K., Babiker, A. et al. Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-73258-4
Received: 09 September 2025
Accepted: 22 September 2026
Published: 04 October 2026
DOI: https://doi.org/10.1038/s41598-026-73258-4
Keywords
来源:Nature 健康护理主题 · nature.com